Skip to main content
Premium Trial:

Request an Annual Quote

Jim Golden, Trevor Hawkins, John Rogers

Premium

Jim Golden has left his position as vice president of research at IDC's market research unit Life Science Insights to join SAIC as chief technology officer for its commercial life science group. Golden told BioInform that he will be responsible for adapting technologies that SAIC has developed for its government and public-sector clients to the pharmaceutical IT market.


Trevor Hawkins will join MDS as chief science and technology officer, a newly created position at the company, on May 2. Hawkins will report to John Rogers, president and CEO of MDS. Hawkins most recently served as president of the molecular diagnostics business unit at GE Healthcare. Previously, he was senior vice president of development and new business initiatives at Amersham Biosciences and director of the Human Genome Project at the Department of Energy's Joint Genome Institute.

Filed under

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.